<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63574">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01660737</url>
  </required_header>
  <id_info>
    <org_study_id>180A12PALL</org_study_id>
    <nct_id>NCT01660737</nct_id>
  </id_info>
  <brief_title>Observational Study With PASCALLERG ® in Patients With Hay Fever</brief_title>
  <official_title>Observational Study With PASCALLERG ® in Patients With Hay Fever</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pascoe Pharmazeutische Praeparate GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pascoe Pharmazeutische Praeparate GmbH</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this observational study is to document the therapeutic use of PASCALLERG ® for
      hay fever. Based on the survey is a decrease in disease-specific symptoms when taking
      PASCALLERG ® over a period of 4 weeks will be documented. In addition to the compatibility
      can be assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are documented male and female patients over the age of one year who suffer from hay
      fever. The traetment time is about a period of 4 weeks with PASCALLERG® tablets.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">September 2012</completion_date>
  <primary_completion_date type="Anticipated">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Efficacy of Pascallerg</measure>
    <time_frame>on average 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Request of Efficacy using a 4-stage scale (very good efficacy, good efficacy, moderate efficacy, no efficacy)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability</measure>
    <time_frame>on average 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Request of Tolerability using a 2-stage scale (very good tolerability, bad tolerability)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Numerical Rating Scale</measure>
    <time_frame>on average 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Influence of allergy on the general well-being (scale from 0-no influence to 10 strong influence)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dry eyes</measure>
    <time_frame>on average 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Itching eyes</measure>
    <time_frame>on average 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Burning eyes</measure>
    <time_frame>on average 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bronchial complaints</measure>
    <time_frame>on average 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sneezing</measure>
    <time_frame>on average 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rhinitis</measure>
    <time_frame>on average 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue / Tiredness</measure>
    <time_frame>on average 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Headache</measure>
    <time_frame>on average 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tearing eyes</measure>
    <time_frame>on average 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Dosage of Pascallerg</measure>
    <time_frame>on average 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Hay Fever</condition>
  <arm_group>
    <arm_group_label>PASCALLERG® tablets in patients with hay fever</arm_group_label>
    <description>Patients with lactose intolerance and / or chromium hypersensitivity are excluded from the observational study.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients from natural practioners and doctors from Germany
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hay fever

        Exclusion Criteria:

          -  Lactose intolerance and / or

          -  Chromium hypersensitivity
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jennifer Lebert, Study Manager</last_name>
    <phone>0049(641)-7960955</phone>
    <email>Jennifer.lebert@pascoe.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bianka Krick</last_name>
    <phone>0049(641)-7960963</phone>
    <email>Bianka.Krick@pascoe.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jennifer Lebert</name>
      <address>
        <city>Gießen</city>
        <zip>35390</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Lebert, Study Manager</last_name>
      <phone>0049(641)-7960955</phone>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 13, 2012</lastchanged_date>
  <firstreceived_date>August 1, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hay fever</keyword>
  <keyword>Pascallerg</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fever</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
